Cargo Talk Feb2021 (2) - Flipbook - Page 11
INDUSTRY Interview
production timelines, volumes, trade
lanes, transportation and storage
requirements and product specificities,
coupled with airfreight capacity crunch,
increased exponentially the number of
difficulties to address and plan for
supply chain professionals. As vaccine
distribution commences, another
major challenge, which remains
to be a concern, is the last mile
delivery to clinics and vaccination
centres in developing economies
where accessibility and cool chain
infrastructure is limited or absent.
Could you please elaborate on
how and why collaboration is
crucial to overcome the supply chain
challenges? How can it be achievable?
q
In achieving effective global
distribution of COVID-19 vaccines,
creating transparency between the
vaccines manufacturers and logistics
industry is paramount. It is precisely
why TIACA and Pharma.Aero are
joining forces in Project Sunrays to
provide the air cargo industry with
clarity of the needs and expectations
from vaccines manufacturers and
better visibility on future COVID-19
vaccines supply chain specifications.
Through Sunrays, we also aim to
provide vaccines manufacturers and
pharma shippers with more visibility on
existing air cargo capabilities, as well
as better understanding of constraints
and needs from air cargo providers to
serve them adequately.
Fostering effective communication
and collaboration between vaccines
manufacturers, shippers, and air cargo
industry players will ensure that once
the vaccine is available in the market,
the air cargo industry is ready to
respond to the needs of the shippers
and transport vaccines in optimal
conditions to all corners of the globe.
According to you what are
service providers’
requirements from the shippers?
qlogistics
Based on our consultation with
vaccines manufacturers, the top
concerns could be summarised in
four areas; speed, security, reliability
and transparency.
Speed: Ensuring no unexpected
delays in every supply chain touch
point
Security: Ensuring that the
shipment is transported with the
highest security standards to mitigate
counterfeits and theft
Reliability: Guaranteed delivery
times maintaining the shipment
integrity
Transparency: Real-time (or
near real-time) tracking, monitoring
and information sharing on shipment
and alerts so that preventative actions
can be undertaken; and there is relaible
information on capabilities of logistics
providers including each cargo facilities
at transit and destination points.
What difference can be observed
qin the pharma supply chain
before and after the pandemic?
It is apparent that the success of
pharma supply chain would depend
on visibility, agility and resiliency.
The demand for pharma products
is expected to grow in the next two
decades. In order to capture and
maximise the opportunity, the entire
network – right from manufacturing
to the global distribution - will need to
come together and work collaboratively
to ensure that the sector remains strong
and agile, providing quality products to
patients in a timely manner.
Another major difference is the
visibility and importance the world
has given the pharma supply chain.
At no other time in history has the
supply chain been so critical to the
well-being of the entire world, with
not only governments, the media
and even the lay person now aware
of the tremendous challenges the
industry faces but also the companies,
organisations and people providing the
solutions to meet those challenges.
TIACA and Pharma.Aero
are joining forces in
Project Sunrays to provide
the air cargo industry with
clarity of the needs and
expectations from vaccine
manufacturers and
better visibility on future
COVID-19 vaccine supply
chain specifications
Transparency is paramount
In achieving effective global
distribution of COVID-19 vaccines,
creating transparency between
the vaccines manufacturers and
logistics industry is paramount.
There should be real-time
tracking, monitoring and
information sharing on shipment
and alerts so that preventative
actions can be undertaken.
FEBRUARY - 2021
CARGOTALK 11
